Article (Scientific journals)
Biotin supplementation causes erroneous elevations of results in some commercial serum 25-hydroxyvitamin d (25OHD) assays.
Carter, G. D.; Berry, J.; Cavalier, Etienne et al.
2020In The Journal of steroid biochemistry and molecular biology, 200, p. 105639
Peer reviewed
 

Files


Full Text
1-s2.0-S0960076019305722-main.pdf
Publisher postprint (1.21 MB)
Request a copy

All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
25-hydroxyvitamin D; Accuracy-based; Biotin interference; DEQAS
Abstract :
[en] The Vitamin D External Quality Assessment Scheme (DEQAS) distributes serum samples globally, on a quarterly basis, to assess participants' performance of specific methods for 25-hydroxyvitamin D (25OHD) and 1,25-dihydroxyvitamin D (1,25-(OH)(2)D). DEQAS occasionally circulates samples containing high levels of substances found in certain clinical situations e.g. 25-OHD(2), 24,25-(OH)(2)D(3), hypertriglyceridemia. The increased availability and use of health supplements containing biotin has led to case reports of assay interference in methods utilizing a biotin-streptavidin detection system. In October 2018, DEQAS included a serum sample (545) containing exogenous biotin (concentration =586 μg/L) which was analyzed by a total of 683 laboratories using 35 different methods. The same serum sample (544) without exogenous biotin was also included in the 5-sample set. All methods (760 laboratories) performed satisfactorily on sample 544 giving an All-Laboratory Trimmed Mean = 50.2 ± 6.5 nmol/L (±SD, CV = 12.9 %). The target value for this sample 544 (& 555) was 47.4 nmol/L as determined by Centers for Disease Control and Prevention (CDC) Atlanta, Georgia using their LC-MS/MS reference method. In contrast, #545 containing the exogenous biotin was reported by only 683 laboratories and gave an All-Laboratory Trimmed Mean = 66.8 ± 37.6 nmol/L (±SD, CV = 56.3 %). As expected, LC-MS/MS methods (143 labs) reported similar results for both 544 = 48.9 ± 4.4 nmol/L (±SD) and 545 = 48.3 ± 4.5 nmol/L (±SD) showing that assays involving chromatographic steps are unaffected by the presence of biotin. Several of the antibody-based assays including Abbott Architect, DiaSorin Liaison, Beckman Unicel and Siemens Centaur are also unaffected by the addition of biotin. Two assays, IDS-iSYS and Roche Total 25OHD, both of which use biotin-streptavidin, exhibit biotin interference yielding values with a significant positive bias for 545 of 102.6 nmol/L ± 78.7 nmol/L (±SD) and 517.8 nmol/L ± 209.8 nmol/L (±SD) respectively. Interestingly, the failure to report sample 545 data from 77 laboratories is due solely to those running Roche Total 25OHD or Roche Vitamin D Total II assays. Given the prevalence of the adversely affected assays (25 % of DEQAS users) and the high volume of 25OHD testing, clinicians using these assays should, where possible, only measure 25OHD when patients are off biotin.
Disciplines :
Laboratory medicine & medical technology
Author, co-author :
Carter, G. D.
Berry, J.
Cavalier, Etienne  ;  Université de Liège - ULiège > Département de pharmacie > Chimie médicale
Durazo-Arvizu, R.
Gunter, E.
Jones, G.
Jones, J.
Phinney, K.
Sempos, C. T.
Twomey, P. J.
Williams, E. L.
Language :
English
Title :
Biotin supplementation causes erroneous elevations of results in some commercial serum 25-hydroxyvitamin d (25OHD) assays.
Publication date :
February 2020
Journal title :
The Journal of steroid biochemistry and molecular biology
ISSN :
0960-0760
eISSN :
1879-1220
Volume :
200
Pages :
105639
Peer reviewed :
Peer reviewed
Commentary :
Copyright © 2020. Published by Elsevier Ltd.
Available on ORBi :
since 04 November 2020

Statistics


Number of views
55 (2 by ULiège)
Number of downloads
3 (2 by ULiège)

Scopus citations®
 
6
Scopus citations®
without self-citations
5
OpenCitations
 
6

Bibliography


Similar publications



Contact ORBi